Janet Gilbertson
Overview
Explore the profile of Janet Gilbertson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
247
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Porcari A, Masi A, Martinez-Naharro A, Razvi Y, Patel R, Ioannou A, et al.
JAMA Cardiol
. 2024 Aug;
9(11):982-989.
PMID: 39167388
Importance: Cardiac amyloid infiltration is the key determinant of survival in systemic light-chain (AL) amyloidosis. Current guidelines recommend early switching therapy in patients with a nonoptimal or suboptimal response regardless...
2.
Porcari A, Fontana M, Canepa M, Biagini E, Cappelli F, Gagliardi C, et al.
Circulation
. 2024 Feb;
149(15):1157-1168.
PMID: 38328945
Background: The extent of myocardial bone tracer uptake with technetium pyrophosphate, hydroxymethylene diphosphonate, and 3,3-diphosphono-1,2-propanodicarboxylate in transthyretin amyloid cardiomyopathy (ATTR-CM) might reflect cardiac amyloid burden and be associated with outcome....
3.
Chacko L, Kotecha T, Ioannou A, Patel N, Martinez-Naharro A, Razvi Y, et al.
Eur J Heart Fail
. 2024 Jan;
26(3):598-609.
PMID: 38247182
Aims: Cardiac involvement is the main driver of clinical outcomes in systemic amyloidosis and preliminary studies support the hypothesis that myocardial ischaemia contributes to cellular damage. The aims of this...
4.
Bomsztyk J, Ravichandran S, Giles H, Wright N, Berlanga O, Khwaja J, et al.
Blood
. 2024 Jan;
143(13):1259-1268.
PMID: 38194690
Amyloidogenic serum free light chains (sFLCs) drive disease progression in AL amyloidosis. Matrix-assisted laser desorption/ionization time of flight mass spectrometry-based FLC assay (FLC-MS) has greater sensitivity than conventional sFLC assays...
5.
Razvi Y, Ioannou A, Patel R, Chacko L, Karia N, Riefolo M, et al.
Eur J Heart Fail
. 2023 Nov;
26(2):383-393.
PMID: 37953725
Aims: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure. A total of 3-4% of individuals of African descent carry a TTR gene mutation encoding the p.(V142I)...
6.
Fontana M, Gilbertson J, Verona G, Riefolo M, Slamova I, Leone O, et al.
N Engl J Med
. 2023 Jun;
388(23):2199-2201.
PMID: 37285532
No abstract available.
7.
Rauf M, Hawkins P, Cappelli F, Perfetto F, Zampieri M, Argiro A, et al.
Eur Heart J
. 2023 Mar;
44(24):2187-2198.
PMID: 36946431
Aims: To perform evaluation of widely embraced bone scintigraphy-based non-biopsy diagnostic criteria (NBDC) for ATTR amyloid cardiomyopathy (ATTR-CM) in clinical practice, and to refine serum free light chain (sFLC) ratio...
8.
Razvi Y, Porcari A, Di Nora C, Patel R, Ioannou A, Rauf M, et al.
Front Cardiovasc Med
. 2023 Feb;
9:1075806.
PMID: 36741843
Aims: Transthyretin cardiac amyloidosis (ATTR-CM) is a progressive and fatal cardiomyopathy. Treatment options in patients with advanced ATTR-CM are limited to cardiac transplantation (CT). Despite case series demonstrating comparable outcomes...
9.
Porcari A, Razvi Y, Masi A, Patel R, Ioannou A, Rauf M, et al.
Eur J Heart Fail
. 2023 Jan;
25(4):515-524.
PMID: 36644836
Aims: Transthyretin amyloid cardiomyopathy (ATTR-CM) is often assumed to be associated with wild-type TTR genotype (ATTRwt) in elderly patients (aged ≥70), some of whom are not offered genetic testing. We...
10.
Rowland H, Blundell R, Chantrey J, Edwards K, Moss A, Stidworthy M, et al.
J Zoo Wildl Med
. 2023 Jan;
53(4):696-704.
PMID: 36640071
Amyloidosis is frequently identified during postmortem examination of captive eastern bongo () in the European Endangered Species Programme (EEP). However, its significance and etiopathogenesis are poorly understood. The objective of...